Trial · NCT07881328
Baseline Dermoscopic Vascular Score and Response to Oral Tranexamic Acid in Facial Melasma
NCT07881328, Phase 4, Not yet recruiting, Allied Hospital Faisalabad
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Baseline Dermoscopic Vascular Score and Response to Oral Tranexamic Acid in Facial Melasma. Trials, record NCT07881328. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881328
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Baseline Dermoscopic Vascular Score and Response to Oral Tranexamic Acid in Facial Melasma
- NCT number
- NCT07881328
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 128 participants, estimated
- Lead sponsor
- Allied Hospital Faisalabad
- Conditions
- Melasma
- Interventions
- Tranexamic acid, Standardised sunscreen and emollient
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Week-12 mMASI in relation to baseline dermoscopic vascular score | Baseline and week 12 | Association between the baseline dermoscopic vascular score (range 0-12; higher = more vascular) and the modified Melasma Area and Severity Index (mMASI; range 0-24; higher = more severe) at week 12. Estimated by multiple linear regression adjusted for baseline mMASI, duration of melasma, age and Fitzpatrick skin type, and reported as the adjusted difference in week-12 mMASI per one-point higher baseline vascular score. |
| Secondary | Change in mMASI from baseline | Baseline, weeks 4, 8 and 12 | mMASI score (range 0-24; higher = more severe) at weeks 4, 8 and 12 compared with baseline. |
| Secondary | Percentage reduction in mMASI and proportion of responders | Baseline and week 12 | Change in total dermoscopic vascular score (range 0-12) from baseline to week 12 in matched facial regions, and its association with absolute change in mMASI. |
| Secondary | Treatment response by dermoscopic phenotype | Week 12 | Exploratory descriptive comparison of week-12 mMASI response between pigmentary (vascular score below 4) and pigmentary-vascular (vascular score 4 or more) phenotypes. |
| Secondary | Inter-observer reliability of the dermoscopic vascular score | Baseline | Intraclass correlation coefficient (two-way mixed effects, absolute agreement, single measure) between two dermatologists independently scoring stored baseline dermoscopic images of the first 40 participants. |
| Secondary | Adherence to tranexamic acid | Weeks 4, 8 and 12 | Percentage of prescribed tablets taken, calculated from tablet counts of returned strips. |
| Secondary | Adverse events, treatment discontinuation and rescue treatment | Baseline to week 12 | Number of participants with adverse events (including thromboembolic events), number discontinuing treatment, and number receiving rescue treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881328
GET https://conductscience.org/api/trials/v1/NCT07881328/registered